Oppenheimer Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Oppenheimer Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.68M	Buy	7,344 +1,655	+29%	+$371K	0.02%	596
2025 Q4	$1.21M	Buy	5,689 +1,248	+28%	+$258K	0.01%	631
2025 Q3	$883K	Buy	+4,441	New	+$828K	0.01%	780
2024 Q4	–	Sell	-7,622	Closed	-$1.14M	–	1155
2024 Q3	$1.14M	Buy	7,622 +695	+10%	+$93.9K	0.01%	699
2024 Q2	$945K	Buy	6,927 +2,048	+42%	+$279K	0.01%	721
2024 Q1	$738K	Sell	4,879 -128	-3%	-$18.3K	0.01%	753
2023 Q4	$631K	Sell	5,007 -277	-5%	-$27.6K	0.01%	813
2023 Q3	$495K	Sell	5,284 -286	-5%	-$26.8K	0.01%	849
2023 Q2	$497K	Sell	5,570 -217	-4%	-$18.9K	0.01%	864
2023 Q1	$620K	Sell	5,787 -103	-2%	-$11.8K	0.01%	794
2022 Q4	$719K	Sell	5,890 -1,586	-21%	-$184K	0.01%	759
2022 Q3	$772K	Sell	7,476 -281	-4%	-$26.6K	0.01%	734
2022 Q2	$721K	Sell	7,757 -3,602	-32%	-$339K	0.01%	770
2022 Q1	$1.33M	Sell	11,359 -715	-6%	-$82.8K	0.02%	659
2021 Q4	$1.62M	Sell	12,074 -1,121	-8%	-$167K	0.02%	618
2021 Q3	$2.1M	Buy	13,195 +2,918	+28%	+$399K	0.03%	521
2021 Q2	$1.35M	Buy	10,277 +2,454	+31%	+$327K	0.02%	660
2021 Q1	$1.01M	Buy	7,823 +3,339	+74%	+$507K	0.02%	718
2020 Q4	$748K	Buy	4,484 +2,133	+91%	+$353K	0.01%	777
2020 Q3	$363K	Buy	2,351 +996	+74%	+$143K	0.01%	883
2020 Q2	$200K	Buy	1,355 +918	+210%	+$126K	﹤0.01%	1015
2020 Q1	$49K	Buy	+437	New	+$56.8K	﹤0.01%	1265

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Oppenheimer Asset Management's ASND Position: Q1 2026 in Review

Oppenheimer Asset Management increased its Ascendis Pharma A/S (ASND) stake by 29% in Q1 2026, buying an estimated $371K and bringing the position to 7,344 shares worth $1.68M. The position accounts for 0.02% of the portfolio, ranked #596.

Oppenheimer Asset Management first reported a position in ASND in Q1 2020 and has held it in 22 quarters since. The position peaked at $2.1M in Q3 2021. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Oppenheimer Asset Management held 7,344 shares of Ascendis Pharma A/S worth $1.68M as of Q1 2026.
Oppenheimer Asset Management bought 1,655 Ascendis Pharma A/S shares in Q1 2026, an estimated $371K.
Ascendis Pharma A/S made up 0.02% of Oppenheimer Asset Management's portfolio in Q1 2026, its #596 holding.
Oppenheimer Asset Management first reported a position in Ascendis Pharma A/S in Q1 2020 and has held it in 22 quarters since.
Oppenheimer Asset Management's Ascendis Pharma A/S position peaked at $2.1M in Q3 2021.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.